- Home
- IIIV vs FLGT Comparison
IIIV vs FLGT Comparison
Compare IIIV & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- FLGT
- Stock Information
- Founded
- IIIV 2012
- FLGT 2011
- Country
- IIIV United States
- FLGT United States
- Employees
- IIIV N/A
- FLGT N/A
- Industry
- IIIV EDP Services
- FLGT Medical Specialities
- Sector
- IIIV Technology
- FLGT Health Care
- Exchange
- IIIV Nasdaq
- FLGT Nasdaq
- Market Cap
- IIIV 612.5M
- FLGT 646.0M
- IPO Year
- IIIV 2018
- FLGT 2016
- Fundamental
- Price
- IIIV $24.86
- FLGT $20.82
- Analyst Decision
- IIIV Buy
- FLGT Buy
- Analyst Count
- IIIV 7
- FLGT 2
- Target Price
- IIIV $29.57
- FLGT $24.00
- AVG Volume (30 Days)
- IIIV 464.6K
- FLGT 313.0K
- Earning Date
- IIIV 05-08-2025
- FLGT 08-01-2025
- Dividend Yield
- IIIV N/A
- FLGT N/A
- EPS Growth
- IIIV 4907.14
- FLGT N/A
- EPS
- IIIV 4.75
- FLGT N/A
- Revenue
- IIIV $241,651,000.00
- FLGT $292,448,000.00
- Revenue This Year
- IIIV N/A
- FLGT $11.79
- Revenue Next Year
- IIIV $5.37
- FLGT $10.45
- P/E Ratio
- IIIV $5.29
- FLGT N/A
- Revenue Growth
- IIIV 5.59
- FLGT 1.71
- 52 Week Low
- IIIV $18.77
- FLGT $14.57
- 52 Week High
- IIIV $29.80
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- IIIV 47.45
- FLGT 57.75
- Support Level
- IIIV $23.63
- FLGT $20.00
- Resistance Level
- IIIV $25.70
- FLGT $21.87
- Average True Range (ATR)
- IIIV 0.90
- FLGT 0.78
- MACD
- IIIV -0.10
- FLGT -0.02
- Stochastic Oscillator
- IIIV 40.20
- FLGT 49.28
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.